72% of Investment, page-20

The entitlement issue closes tomorrow so if you were selling to fund the take up of your entitlement then yesterday was the last day to do so if you wanted a clean transfer of funds without committing any additional dollars.

I would be very encouraged by a full take up of rights from a combination of existing shareholders plus Baker Young clients.

I'm sure we will see in the quarterly how dire the cash situation is with the R&D tax refund largely going to Berlin Pharma (the gift that keeps on taking).

But looking forwards and not backwards will see the company with close to $4m in the bank with key value adding milestones such as Zolpimist approval and an Anagrelide update not too far away.

Not to mention whatever else is simmering in the background.